Yoshimasa Shiraishi

机构：Kyushu University, Kyushu University Hospital · ORCID：0000-0001-5015-193X

发表论文 190 篇 · 总被引 1865 次 · h-index 24

代表论文

• Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (2024 · New England Journal of Medicine · 被引 343)
• Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial (2024 · The Lancet Respiratory Medicine · 被引 49)
• Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834 (2025 · Journal of Clinical Oncology · 被引 33)
• Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON) (2025 · Journal of Thoracic Oncology · 被引 18)
• Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC (2025 · Nature Communications · 被引 17)
• Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004) (2024 · European Journal of Cancer · 被引 12)